

"TEMPUS

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

May 28, 2025

CHICAGO--(BUSINESS WIRE)--May 28, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus' ongoing commitment to accelerating scientific discovery and delivering data-driven insights that improve patient outcomes.

Since its founding in 2015, Tempus has partnered with leading academic institutions, community health systems, and biopharma organizations to drive forward cutting-edge research and advance precision medicine. Leveraging its AI-powered platform, Tempus offers one of the most comprehensive suites of solutions supporting both clinical and therapeutic research. Notable contributions include:

- Tempus has enabled critical advancements across a broad spectrum of initiatives including approximately 1,000 biopharma research projects and almost 500 provider-led research initiatives through its diagnostic portfolio, de-identified multimodal dataset, and biological modeling capabilities.
- Diagnostic assays that have generated clinically-relevant insights across more than 200 projects.
- Tempus' biological modelling lab has supported approximately 65 research initiatives, advancing understanding in areas such as therapy selection and drug discovery.

"From day one at Tempus, our mission has been to empower researchers with the data and insights they need to drive better outcomes," said Eric Lefkofsky, Founder and CEO at Tempus. "We have made significant progress toward that goal by delivering at a scale few others have achieved. While we're proud of what we've accomplished, we are even more excited about the opportunity to exponentially expand our impact in the years ahead, as new and emerging artificial intelligence tools are allowing us and partners to unlock insights from the data we have aggregated at an almost unimaginable scale."

"When I was recruited to Vanderbilt University Medical Center in 2018 to build a global precision oncology program, I was struck by the forward thinking and visionary leadership of Eric and his team at Tempus. Their premise that they were not just a tumor sequencing company, but also a data company, really resonated with me and what we wanted to accomplish at the Vanderbilt-Ingram Cancer Center," stated Ben Park, MD, PhD, Director of the Vanderbilt-Ingram Cancer Center. "Our resulting collaboration these past seven years has been enormously successful. Since partnering with Tempus, we have been able to offer our patients state-of-the-art diagnostic testing that is unparalleled, and simultaneously we leverage this data, as well as Tempus' database, for research that addresses unmet needs in cancer care."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical and therapeutic research, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250528572864/en/): <https://www.businesswire.com/news/home/20250528572864/en/>

Erin Carron
media@tempus.com

Source: Tempus AI, Inc.